Pergi ke luar talian dengan aplikasi Player FM !
Update from ASCO GI 2023 Ep 2: lower GI cancer highlights
Manage episode 442027520 series 3293376
COR2ED Medical Education: This episode, covers the highlights on colorectal cancer from ASCO GI 2023. Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and Prof. Shubham Pant (MD Anderson Cancer Center, Houston, TX, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice.
The experts start by discussing the SUNLIGHT trial which studied the use of trifluridine/tipiracil plus bevacizumab as third-line treatment in refractory colorectal cancer. The discussion then moves on to a trial which evaluated the kinetics of post operative circulating cell-free DNA and its impact on minimal residual cell detection in patients with stage I-III colorectal cancer.
The third abstract the experts discussed was a phase I trial which study botensilimab plus balstilimab in MSS colorectal cancer patients. Finally they discuss the long term results of NRG-GI002, a phase 2 trial which looked at the use of total neoadjuvant therapy in locally advanced rectal cancer.
89 episod
Manage episode 442027520 series 3293376
COR2ED Medical Education: This episode, covers the highlights on colorectal cancer from ASCO GI 2023. Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and Prof. Shubham Pant (MD Anderson Cancer Center, Houston, TX, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice.
The experts start by discussing the SUNLIGHT trial which studied the use of trifluridine/tipiracil plus bevacizumab as third-line treatment in refractory colorectal cancer. The discussion then moves on to a trial which evaluated the kinetics of post operative circulating cell-free DNA and its impact on minimal residual cell detection in patients with stage I-III colorectal cancer.
The third abstract the experts discussed was a phase I trial which study botensilimab plus balstilimab in MSS colorectal cancer patients. Finally they discuss the long term results of NRG-GI002, a phase 2 trial which looked at the use of total neoadjuvant therapy in locally advanced rectal cancer.
89 episod
Kaikki jaksot
×Selamat datang ke Player FM
Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.